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various elective knee surgeries with rFVIIa coverage in hemo-
philiacs with inhibitors from a US payer perspective.
METHODS: A literature-based Markov model was used to
compare the direct medical costs and quality-adjusted life-years
(QALYs) of 2 hypothetical cohorts of hemophiliacs with inhibi-
tors and frequent bleeding episodes: one undergoing elective
orthopedic surgery and the other not undergoing surgery. Based
on the published literature, surgery was assumed to reduce bleed-
ing frequency by 82%, from 9.13 to 1.64 episodes per year, and
improve pain and quality of life. Surgery costs included periop-
erative rFVIIa costs, inpatient and rehabilitation care, and repeat
procedures. RESULTS: Estimated knee surgery costs ranged from
$677,000 (in knee arthrodesis [KA]) to $840,000 (in total knee
replacement [TKR]). Surgery reduced the incidence of bleeding
episodes and resultant costs. Speciﬁcally, the cumulative dis-
counted savings in bleeding-related costs were $537,000 and
$991,000 at 5 and 10 years, respectively. Overall, the cost of
surgery was offset within 7 to 9 years of the index procedure,
depending on the surgery. Surgery also resulted in discounted net
gains of 1.88 and 3.47 QALYs after 5 and 10 years, respectively.
The cost per QALY gained with KA and TKR fell under $50,000
during the 6th and 7th years, respectively. Changes in assump-
tions regarding prophylaxis regimen, survival, baseline bleeding
frequency, patient weight, and rate of repeat surgery affected the
results to various degrees. CONCLUSION: Despite high upfront
costs, knee surgery with rFVIIa in hemophiliacs with inhibitors
leads to cost savings and QALY gains within a few years, prima-
rily due to reductions in bleeding episodes.
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OBJECTIVES: The cost-effectiveness of dasatinib was evaluated,
comparing dasatinib (2 ¥ 70 mg) to 800 mg imatinib per day in
imatinib-resistant chronic CML, from the perspective of the
Spanish health care system. METHODS: A Markov model was
developed (cycle length one month) which incorporates clinical,
epidemiological and cost data to assess the cost-effectiveness of
dasatinib compared to imatinib in imatinib-resistant chronic
CML patients (95% of CML patients in Spain). The model
allows the simulation of the distribution of patients over the
chronic, accelerated and blast phase of CML. At model entry,
patients are classiﬁed according to initial best response rates,
from randomised Phase II clinical trial data comparing dasatinib
with imatinib (800 mg) in imatinib resistant patients. Distinction
is made between no response, complete hematological response,
partial cytogenetic response and complete cytogenetic response.
Disease progression depends on initial response to treatment.
Treatment costs were obtained from eSalud, a health care cost
database in Spain. Health effects and costs were counted until all
patients reached the “death” state. Both costs and effects were
discounted annually at 3.5%. The robustness of the results was
tested in deterministic sensitivity analyses. RESULTS: In the base
case analysis, treatment with dasatinib is associated with a gain
of 0.64 quality adjusted life-years (QALY) and cost savings of
€16,600, resulting in an estimate of dominance for dasatinib.
Sensitivity analysis of key variables conﬁrmed that results remain
located in the south-east quadrant of the CE-plane (i.e. domi-
nance). CONCLUSION: Compared to imatinib, dasatinib is
associated with increased life expectancy and lower overall costs,
indicating that dasatinib is a dominant treatment strategy for the
treatment of patients with CML who are resistant to imatinib.
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OBJECTIVES: In 2004 the German government limited the
adoption of assisted reproductive technology (ART) treatment
costs by statutory health insurance from 100 to 50 percent.
Furthermore age limits were adapted and the number of funded
ART cycles was restricted from four to three cycles. The aim of
this study was to estimate the effect of restricting fertility services
from a health fund’s perspective. METHODS: Over the period of
2002 to 2005 our study investigated the changes in the number
of ART cycles, treatment costs and birth rates after assisted
reproduction. The analysis is based on health insurance fre-
quency statistics including fee schedule items reimbursed by
health insurance funds. ART cycles included intrauterine insemi-
nation (in natural or stimulated cycles), in vitro fertilisation and
intracytoplasmic sperm injection. RESULTS: The number of
funded ART cycles ranged from 73,405 in 2002, 104,542 in
2003, 35,352 in 2004 to 32,099 in 2005. The number of ART
cycles increased expectedly between 2002 and 2003. The gain
add up to 42%. In 2004 the number of ART cycles decreased by
66%. This downward trend continued in 2005 with a decline by
another 9%. In 2004 treatment costs funded by the health insur-
ance decreased by 84% according to the limitation of reimburse-
ment. Corresponding to the falling number of ART cycles the
birth rate depending on ART decreased too. However, the
decrease had no statistically signiﬁcant impact on the common
birth rate in Germany. CONCLUSION: With restricting fertility
services the number of ART cycles declined statistically. The
absolute number of births decreased too. One of the reasons may
be high co-payments which will mean many patients can not
longer afford this special kind of medical treatment.
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OBJECTIVES: To ﬁnd evidence on the economic impact of
anemia and transfusion in MDS and estimate the prevalence
of transfusion-dependent MDS patients in Germany and make
a ﬁrst appraisal of the economic impact of these patients.
METHODS: Literature search via PUBMED was systematically
conducted (covering January 1996 to December 2006) using
deﬁned search terms, e.g. Myelodysplastic Syndrome AND
Transfusion AND Cost and cost analysis OR cost of illness. From
the German transfusion medicine’s perspective desk-top
researches were conducted to evaluate the economic burden of
transfusion-dependency of MDS patients in Germany. RESULTS:
Three cost-analyses regarding transfusion costs of MDS patients
were identiﬁed with major distinctions in study design, methods,
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and comparative treatments. Based on data from the literature
review, approximately 50% of MDS patients are transfusion
dependent across all risk groups. In Germany, between 3800 and
5400 MDS patients needed transfusions in 2005. With an esti-
mated growth rate of approximately 6% per year, MDS will
occur in between 9,800 and 13,900 patients in 2010. Taking into
account 24 erythrocyte concentrates (EC) per MDS patient per
year, 2% to 3% of the whole erythrocyte production in Germany
is allocated to MDS. This calculates to total medical transfusion
costs between 8 and 23.5 million Euro depending on the number
of transfusion-dependent patients and unit costs of EC. CON-
CLUSION: A comprehensive cost-of-illness study covering all
settings of care is necessary to learn about MDS resource con-
sumption and economic consequences. Rational allocation of
blood will be of special public health interest in the future due to
the demographic development in Germany. The increasing scar-
city of blood creates a strong need for therapies which terminate
or reduce transfusion dependency. Due to the fact that innovative
therapeutics for MDS will be available soon, it is important to
evaluate their economic consequences with a special focus on
their blood saving potentials.
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OBJECTIVES: Investment views have been more or less
neglected in economic evaluations. Fortunately, investments can
be efﬁciently and easily assessed by evaluating the most uncer-
tain feature of investment—Time—from two perspectives. The
innovation, Positive Investment Interval (PII), its estimation and
interpretation are presented here in relation to Payback Period
(PP) with a safety example of Hemophilia A (HA), where the
best safety is achieved using plasma/albumin-free methods
(PFM). METHODS: PII estimates the interval when sc. safety
costs are compensated by the treatment costs of adverse event/
events (AE). PP, on the other hand, estimates the time when the
safety costs become compensated by the AE treatment costs.
RESULTS: Both PII and PP are acceptable if the effectiveness of
treatment options is equal. PII estimates the interval when
investment to e.g. safety offers positive margin. In simple terms,
PII is interval when no security threats should occur, if more
risky treatment is used. Mathematically, PII compares the incre-
mental costs of new minus old therapy (e.g. safety costs) to the
incremental AE costs of old minus new therapy in a given inter-
val (e.g. annual budgeting period). PP is the reversed version of
PII. Stochastic PIIs can be presented in an AE costs-safety costs
plane. In HA case, when base-case PIIs for annual PFM Advate
vs. non-PFM Kogenate investment were 1–7 years depending on
patient’s weight, age, and treatment modality, were PPs 2–11
months. Longer PII, the better and shorter PP, the better. Thus,
PII > PP is usually a potentially good and beneﬁcial investment
depending on the expected time horizons of possible AEs or
other patient security risks. CONCLUSION: PII is related to
e.g. safety need as time and, thus, it has hands-on interpretation
for political debate. PII can be compared to the time intervals of
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OBJECTIVES: Our objective is to develop a quantitative, model-
based protocol simulation approach for evaluating the clinical
and economic effects of adverse drug outcomes related to genetic
variation at early stages of drug or test development, using war-
farin pharmacogenomics as a case-study. METHODS: We im-
plemented a previously published (Hamberg et al. (2007))
population pharmacokinetic/pharmacodynamic (PK/PD) model
of warfarin distribution and effect that incorporates the effects of
genetic variation in the CYP2C9 and VKORC1 genes and other
relevant demographic variables. We simulated outcomes (INR
distribution) of a non-pharmacogenomic-based warfarin dosing
protocol, and plan to simulate various pharmacogenomic-based
dosing protocols and then integrate these results with pharma-
coeconomic simulation models. RESULTS: INRs were modeled
for 500 simulated patients using the same patient demographics
(median and range) as those reported in the Hamberg analysis.
The 5 mg/daily INR nomogram of Kovacs et al. (2003) was
simulated. Baseline INRs were uniformly distributed over a range
of 0.9 to 1.3. The INR at day 6 after initiation of therapy ranged
from 0.97 to 10.31 with a median of 3.61. Median INR grouped
by CYP2C9 expression ranged from 3.17 for *1*1 patients to
5.29 for *3*3 patients. INR variations are linked to the risks of
bleeding and stroke, and ultimately to the pharmacoeconomic
outcomes of costs and quality-adjusted life years. CONCLU-
SION: ‘P-cubed’ (P3) modeling will be feasible only when sufﬁ-
cient population PK/PD data are available and valid long-term
linkages can be made. It may serve as a tool to explore the
robustness of such linkages and probe alternative therapeutic
scenarios. Although our ﬁndings are preliminary to date,
P3-modeling may provide a useful quantitative framework to
help inform pharmacogenomic trial design, regulatory decisions,
and potentially clinical guidelines and reimbursement policies.
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OBJECTIVES: The recent FENOC 2006 comparative trial
reported comparable efﬁcacy for rFVIIa and APCC in the treat-
ment of joint bleeds in hemophiliacs with inhibitors. A literature-
based Bayesian meta-regression analysis was carried out to place
these results within the context of earlier, non-comparative
studies and to identify key variables inﬂuencing treatment efﬁ-
cacy. METHODS: A systematic search of the literature identiﬁed
15 studies reporting usable and relevant data, which were pooled
in a Bayesian random-effects survival model. A repeating Gomp-
ertz hazard function was selected to model an initial increase in
the hazard of bleed resolution after each injection, followed by a
decrease until the next injection was administered. Model cova-
riates included medication type and the combination of the time-
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